Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

By N. Penel, B. Bui, J. Bay, D. Cupissol, I. Ray-Coquard, S. Piperno-Neumann, P. Kerbrat, C. Fournier, S. Taieb, M. Jimenez and 6 more. Journal of Clinical Oncology, 2008

631 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Oncology

View Paper: https://www.semanticscholar.org/paper/a23c916a5026b71ef0b1cdb04e99dcbb007ccd71

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. E. Ewing
2. J. Bovée
3. J. Broto
4. A. Tos
5. T. Gil
6. A. Gronchi
7. S. Ferrari
8. P. Reichardt

Citations in the corpus

• Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2012, background): “In angiosarcoma, taxanes are an alternative option, given their high antitumour activity in this specific histological type [20] [III, B].”
• Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “Angiosarcoma is highly sensitive to taxanes, which can be a treatment option in this histological subtype [III, B] [30].”